Drug Type Gene therapy |
Synonyms- |
Target |
Action modulators |
Mechanism PRKN modulators(parkin RBR E3 ubiquitin protein ligase modulators) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhasePendingPreclinical |
First Approval Date- |
Regulation- |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Parkinson Disease | Preclinical | United States | 01 Jan 2022 |





